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Abstract
Background: This retrospective analysis is focused on the efficacy and safety of radioimmunotherapy (RIT) with
Zevalin
® in nine patients with recurrent follicular lymphoma (FL) who were treated in a consolidation setting after
having achieved complete remission or partial remission with FCR.
Methods: The median age was 63 yrs (range 46-77), all patients were relapsed with histologically confirmed CD20-
positive (grade 1 or 2) FL, at relapse they received FCR every 28 days: F (25 mg/m
2x 3 days), C (1 gr/m
2 day 1) and
R (375 mg/m
2 day 4) for 4 cycles. Who achieved at least a partial remission, with < 25% bone marrow
involvement, was treated with
90Yttrium Ibritumomab Tiuxetan 11.1 or 14.8 MBq/Kg up to a maximum dose 1184
MBq, at 3 months after the completion of FCR. The patients underwent a further restaging at 12 weeks after
90Y-
RIT with total body CT scan, FDG-PET/CT and bilateral bone marrow biopsy.
Results: Nine patients have completed the treatment: FCR followed by
90Y-RIT (6 patients at 14.8 MBq/Kg, 3
patients at 11.1 MBq/Kg). After FCR 7 patients obtained CR and 2 PR; after
90Y-RIT two patients in PR converted to
CR 12 weeks later. With median follow up of 34 months (range 13-50) the current analysis has shown that overall
survival (OS) is 89% at 2 years, 76% at 3 years and 61% at 4 years. The most common grade 3 or 4 adverse events
were hematologic, one patient developed herpes zoster infection after 8 months following valacyclovir
discontinuation; another patient developed fungal infection.
Conclusions: Our experience indicate feasibility, tolerability and efficacy of FCR regimen followed by
90Y-RIT in
patients relapsed with grades 1 and 2 FL with no unexpected toxicities. A longer follow up and a larger number of
patients with relapsed grades 1 and 2 FL are required to determine the impact of this regimen on long-term
duration of response and PFS.
Background
Follicular lymphoma is the most common type of indo-
lent non-hodgkin lymphoma (NHL) in Western coun-
tries and is typically characterized by recurrence of
disease. There is usually a pattern of repeated remissions
and relapses until patients become refractory to treat-
ment. The duration of remissions becomes shorter with
repeated induction attempts. Transformation to more
aggressive NHL occurs in 15% to 50% of the patients at
5 years.After first relapse patients in otherwise good
health are candidate for salvage chemotherapy: combina-
tion chemotherapy, immunotherapy, and for some
patients with good performance status and responsive
disease, myeloablative therapy with stem-cell rescue.
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this patient population and FCR regimen has provided
encouraging results as initial or salvage therapy in patients
with CLL or indolent NHL [1,2]. Radioimmunotherapy is
also an excellent modality in the treatment of NHL; the tar-
get antigen, radionuclide emission properties, and chemical
stability of radioimmunoconjugates are important factors
that contribute to the effectiveness of RIT.
90 Yttrium can
d e l i v e rah i g hb e t ae n e r g yt ot u m o r( 2 - 3M e V )a n d
90
Yttrium Ibritumomab Tiuxetan (
90 Y -RIT ) - Zevalin
® -
consists of the anti-CD20 monoclonal antibody ibritumo-
mab (an IgG1k antibody which is the murine parent immu-
noglobulin to rituximab) covalently bound to the chelating
agent tiuxetan and radiolabeled with
90 Yttrium.
Furthermore recently FIT study has shown that conso-
lidation of first remission with
90 Yttrium in advance-
stage follicular lymphoma is highly effective with no
unexpected toxicities, prolonging progression free survi-
val (PFS) by 2 years [3,4]. Then consolidation with
90
Yttrium after first line induction therapy, may allow
more patients, with disseminated disease at diagnosis, to
benefit from radioimmunotherapy and may present an
attractive treatment option, particulary in older patients
(age ≥ 60 years) who represent rougly 50% of patients
with newly diagnosed indolent NHL.
90 Y-RIT also has been reported to be effective in
patients with relapsed or refractory FL [5-7]. In this arti-
cle we describe our experience with
90 Y- R I Tc o n s o l i -
dation in nine patients relapsed with grade 1 and 2 FL
patients, responding to FCR.
Methods
Patients
The patients who were included in the current retrospec-
tive analysis had CD20+ histologically confirmed relapsed
grade 1 or 2 follicular lymphoma, all patients provided
informed consent according to institutional guidelines.
Patients had received at least one prior treatment, were
age ≥ 18 years, with WHO performance status of 0 to 2,
h a da c h i e v e da tl e a s tP Ra tt h ec o m p l e t i o no fF C R ;t h e
last chemotherapy with or without rituximab was admi-
nistered at least three months before start of FCR; no
patient under maintenance therapy with rituximab was
considered. Patients had less than 25% bone marrow
involvement by lymphoma on biopsy before start of RIT;
an absolute neutrophil count ≥ 1.5 × 10
9 L; hemoglobin
levels ≥ 9 gr/dl and a platelet count ≥ 100 × 10
9 L.
Patients with central nervous system (CNS) involvement,
positive HIV were excluded from the analysis.
Treatment
Patients at relapse had received 4 cycles of FCR: fludara-
bine at a dose of 25 mg/m
2 i.v. on days 1 to 3; cyclopho-
sphamide at a dose of 1 gr/m
2 i.v. on day 1 and rituximab
at a dose of 375 mg/m
2 was given on day 4 of each cycle
every 28 days. Patients were restaged with CT scan, FDG
PET/CT and bone marrow biopsies after the last course
of FCR: who had achieved at least a partial remission,
with < 25% bone marrow involvement, received 12 weeks
since the last course of FCR two infusions of rituximab
250 mg/m
2 one week apart, with the first infusion admi-
nistered alone and the second infusion followed immedi-
ately by
90 Y-RIT 14.8 MBq/Kg - 11 MBq/Kg, if the
platelet number was between 100 × 10
9/L and 149 × 10
9/
L, not to exceed a total of 1.184 MBq administered as a
slow i.v. push over 10 minutes (Figure 1).
Assessments
All patients included in the analysis were restaged with
CT scan, FDG-PET and bilateral bone marrow biopy at
4-5 weeks after the last cycle of FCR and 12 weeks after
90 Y-RIT. No real-time quantitative PCR (RQ-PCR) eva-
luation of pheripheral or marrow blood samples for bcl-
2 t(14;18) translocation was performed at baseline and
thereafter. Safety was assessed by adverse events (AEs),
with toxicity grading based on the National Cancer
Institute Common Toxicity Criteria (version 2), clinical
laboratory evaluations, and physical examinations. OS
was calculated from the date of FCR treatment to the
date of death from any cause; OS was analyzed by using
the Kaplan-Meier method.
Results
Patients characteristics
In this retrospective analysis, from August 2005 to July
2010, 9 patients had received FCR 4 cycles followed by
90 Y - R I T( 6p a t i e n t sa t1 4 . 8M B q / K g ,3p a t i e n t sa t1 1 . 1
MBq/Kg). Baseline characteristics are presented in
(Table 1). The median age was 63 years (range 46-77).
All patients were relapsed patients: 2 patients received a
prior therapy, 5 patients received 2 prior treatments and
2 patients had received 3 regimens. Seven patients were
previously treated with rituximab plus chemotherapy,
two patients had no previous rituximab treatment his-
tory, one patient received also high-dose therapy fol-
lowed by autologous stem cell transplantation (Table 2)
F:   25 mg/m2 i.v days 1-3       
C:  1gr/m2 i.v day 1
R:  375mg/m2 i.v day 4
FCR-28  
4  CYCLES
Zevalin®
11.1-14.8 
MBq/Kg
CR/CRu
or PR
Restage before RIT:
CT, PET, BMB 
Restage 12 weeks 
After Zevalin®
CT, PET, BMB 
Figure 1 Treatment schema.
Pisani et al. Journal of Experimental & Clinical Cancer Research 2011, 30:16
http://www.jeccr.com/content/30/1/16
Page 2 of 5Efficacy and safety
After 4 cycles FCR seven patients obtained CR and
2 PR, two patients in PR converted to CR after RIT.
With a median observation period of 34 months (range
13- 50) the OS is 89% at 2 years, 76% at 3 years and
61% at 4 years. Grade 3 or 4 neutropenia occurred in 8/
9 patients treated with FCR and in 9/9 patients assessa-
ble after
90 Y-RIT. Subsequently to radioimmunotherapy
the median neutrophil nadir was 0.8 × 10
9/L (range
0.1-0.9 × 10
9/L) at week 5, the median platelet count
nadir was 49 × 10
9/L (range 17-80 × 10
9/L) at week 5.
The median duration nadir for both neutrophils or pla-
telets was 14 days. One patient developed herpes zoster
infection after 8 months following valacyclovir disconti-
nuation; another patient developed fungal infection.
Both infections disappeared after specific treatment.
After a median observation period of 34 months one
patient developed t-MDS (treatment-related myelodys-
plastic syndrome) at 26 months after
90 Y-RIT. This
patient before FCR and consolidation with RIT had
received three previous regimens: at diagnosis 6 courses
of CHOP, at first relapse, 3 years later, four courses of
FM/R (fludarabine, mitoxantrone plus rituximab) and
after one year, at the second relapse, he received cyclo-
phosphamide plus dexamethasone and rituximab,
remaining in CR for 48 months. He died at 73 years of
age for sepsis during support therapy for t-MDS. Other
two patients have died: one for acute renal failure and
one for ictus cerebri.
Discussion
In follicular lymphoma retreatment typically yields pro-
gressively less satisfactory responses than the prior treat-
ment, eventually leading to refractory disease, and the
question remains regarding whether the survival of
patients with FL is improving with new treatment
regimens.
In the current retrospective analysis, nine patients
with relapsed grade 1 and 2 FL, responding to FCR regi-
men and consolidated with
90 Y-RIT obtained a signifi-
cant high rate of response with 100% of CR and
acceptable toxicity. After a median observation period of
34 months 6/9 patients were alive in CR and 7/9 were
already treated with at least two prior regimens. Two
patients converted PR to CR after consolidation with
90
Y-RIT. This conversion was already shown in published
phase III study (FIT-study) in first-line FL [3,4], and in
previous phase II studies of consolidation with the
radioimmunotherapy agent
131 I-tositumomab after first-
line induction [8,9],
Table 1 Patient characteristics
Number of patients = 9
Male/Female 3/6
Median Age (Range) 63 (46-77) years
Disease stage at diagnosis at start of FCR
I1 0
II 1 5
III 1 3
IV 6 1
Bone marrow involvement
0% 7
10% to ≤ 25% 2
Extranodal involvement 1 (liver)
FLIPI
Low 1
Low-intermediate 6
Intermediate-high 2
Bulky disease 1
B-symptoms 0
Prior therapy including rituximab
No 2
Yes 7
Number of previous regimens
12
25
>2 2
Table 2 Clinical characteristics
Patients No Sex/Age (y) Previous treatment Response to FCR Response to RIT Follow up (mo) since RIT
1 F/68 CHOP/R, radiotherapy CR CR 50 alive in CR
2 F/66 Radiotherapy, CHOP/R CR CR 34 alive in CR
3 F/57 CHOP/R PR CR 44 alive in CR
4 F/67 CHOP/R, radiotherapy CR CR 13 dead in CR
5 M/46 CHOP/like, ASCT, IFN maintenance for 24 months PR CR 28 alive in CR
6 F/61 MACOPB/R CR CR 39 alive in CR
7 M/69 CHOP,FM/R, Cy Dex/R CR CR 30 dead in CR
8 M/57 Chlorambucil, MACOPB/R CR CR (t-MDS) 32 dead in CR
9 F/77 Chlorambucil, radiotherapy CR CR 44 alive in CR
CHOP: cyclophosfamide, doxorubicin, vincristine, prednisone; R: Rituximab; MACOPB: Methotrexate, Doxorubicin, cyclophoshamide, vincristine, prednisone,
bleomycin,; ASCT: autologous stem cell transplantation; IFN: alpha interferon, FM: fludarabine, mitoxantrone; Cy Dex: cyclophosphamide, dexamethasone; t-MDS:
treatment-related myelodysplastic syndrome.
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90 Y-RIT to improve
responses also in patients who are pretreated with ritux-
imab based combination therapy [3]; even if in our two
patients there is no proof that this conversion was due
to RIT and not to a late response to FCR. In the FIT
study close to 17% of the patients in the control arm,
converted from PR to CR during watchful waiting [3],
b u ti ti st ob ec o n s i d e r e dt h a to u rt w op a t i e n t sh a d
higher risk of resistance being already pretreated.
In our analysis the OS at 2 years was 89%, at 3 years
76% and at 4 years 61%. In another study conducted on
patients with recurrent FL, treated with FCR, a 75% OS
rate at 4 years and a 61% PFS rate at 4 years were regis-
tered, but in that study only 7% of patients had been
treated previously with rituximab and furthermore no
patients had received combination treatment with che-
motherapy plus rituximab [10]. Regarding AEs there was
a high incidence of neutropenia and thrombocytopenia
but hematologic toxicities grade 3 or 4 did not require
transfusion but growth factor support was utilized in
the majority of patients during FCR treatment, and in
all of them after
90 Y-RIT. Despite the high incidence of
grade 3 or 4 neutropenia there were no patients requir-
ing hospitalization for infection. We registered a case of
herpes zoster infection after 8 months following valacy-
clovir discontinuation that disappeared after retreat-
ment, and a case of fungal infection by conidiobolus,
developed 10 months after
90 Y-RIT and disappeared
with itraconazole treatment. Other previous studies have
already shown the low percentage of patients requiring
hospitalization for infections [3,5] and a favorable safety
profile [11,12]. A case of t-MDS with complex karyotype
was diagnosed 26 months after
90 Y-RIT consolidation:
this patient received 3 previous regimens before FCR
plus
90 Y-RIT, as already mentioned he died for sepsis.
This patient had been previously treated with topoi-
somerase II inhibitors, alkylating agents and purine
nucleoside analogs. Czuczman et al. reported an inci-
dence of t-MDS and t-AML (treatment-related acute
myeloid leukemia) after
90 Y-RIT of 0.3% per year after
the diagnosis of NHL and 0.7% per year after treatment.
Most patients with t-MDS or t-AML had multiple cyto-
genetic aberrations, commonly on chromosomes 5 and
7, suggesting an association with previous exposure to
chemotherapy. In Czuczman study these malignancies
were diagnosed at a median of 5.6 years (range 1.4 to
13.9) after the diagnosis of NHL and 1.9 years (range
0.4 to 6.3) after radioimmunotherapy [13]; the conclu-
sion of this study was that the annualized incidences of
t-MDS and t-AML were consistent with that expected
in patients with NHL who have had extensive previous
chemotherapy and do not appeared to be increased after
90 Y-RIT. Cytogenetic testing before treatment with RIT
may identify existing chromosomal abnormalities in
previously treated patients, particularly those who have
been treated with alkylating agents and purine analogs
and would be at higher risk to develop t-MDS or
t-AML.
In our series the other two death were not in relation
of progressive disease and all three deceased patients
obtained CR before
90 Y-RIT and died still in CR.
Additional follow up is required to determine potential
long-term AEs with
90 Y-RIT consolidation. In our
patients, the response to
90 Y-RIT was assessed by CT,
bone marrow biopsies and also with FDG-PET, this ima-
ging procedure is useful to evaluate disease extension
before treatment and response to RIT in FL. A recent
study has shown that the post-RIT PET result is an
independent predictive factor of PFS [14].
Conclusions
This retrospective analysiso fn i n er e l a p s e dg r a d e s1o r
2 FL patients with median age 63 years, heavily pretreated,
demonstrates that FCR followed by
90 Y-RIT was feasible,
safe and yielded high overall and complete response rates
in patients with recurrent FL. Hematologic toxicity
occurring with FCR or with RIT were clinically controlla-
ble and acceptable in a population composed mainly of
patients with a history of prior treatment using rituximab
plus chemotherapy. A longer follow up and a larger
number of patients with relapsed grades 1 and 2 FL are
required to determine the impact of this regimen on
long-term duration of response and PFS, but this preli-
minary results suggest that this regimen could be an
option to be used for the treatment in this setting of
patients, specially at age of 60-75 and earlier in first
relapse; further studies will help to clarify the best strat-
egy for incorporating RIT into the treatment algorithm
of these patients.
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